KLIFO
Erik Zobel is a highly experienced professional in quality assurance within the biopharmaceutical industry, currently serving as Senior Director of Quality Assurance, QP & RP at KLIFO since April 2022. Prior to this role, Erik held the position of Head of QA at Orphazyme A/S, overseeing global quality operations and successfully leading the company's transformation to commercial readiness for product launch in the US and EU. Erik has a strong background in quality systems and regulatory compliance, having held significant positions at AGC Biologics, Pfizer, Bavarian Nordic, Novo Nordisk, Scanpharm, and Ferring A/S. Erik’s educational qualifications include a MSc in Pharmacy from Danmarks Farmaceutiske Universitet and a Graduate Diploma in Business Administration from Copenhagen Business School.
This person is not in any teams
KLIFO
KLIFO is an integrated North-European drug development consultancy with significant experience in partnering with pharmaceutical and biotech companies. We enable our partners to maximise opportunity, mitigate risks, drive innovation and achieve efficient project advancement. We offer end to end solutions across all drug development areas, including strategic project management, regulatory affairs, clinical development, clinical trial supply, quality assurance (QA), Chemistry Manufacturing and Controls (CMC) development, non-clinical development and pharmacovigilance in relation to the development of pharmaceutical products. We provide strategic advice as well as operational support in all these areas, and we partner with clients on portfolio strategies, project development strategies and project execution. KLIFO has offices in Denmark, Sweden, Germany and The Netherlands and employs more than 150 highly skilled employees.